LONDON--(BUSINESS WIRE)--Quantzig, a global data analytics and advisory firm, that delivers actionable analytics solutions to resolve complex business problems announces the completion of its FREE downloadable resource that explains ‘How Top European Pharma Companies Like Bayer are Tackling COVID-19.’
What’s in it for you?
- Learn how supply chain leaders from leading European pharma companies are responding to the supply chain disruptions
- Gain insights on the challenges facing the European pharma industry
- Learn how you can tackle the ongoing crisis and supply chain risks with the help of robust supply chain risk management strategies
The ultimate success of pharma companies depends on their ability to cater to the dynamic needs of the market. Request a FREE proposal to learn how we can help you build resilient supply chains to cater to the market needs.
The interconnected, complex supply chains of European pharma companies are inevitably subject to disruptions. Owing to the complexities and the ongoing crisis creating resilient supply chains and building a systematic supply chain risk management framework has become the ‘need of the hour’. Leading pharma companies relying on reactive measures previously are now looking to improve their supply chain risk management capabilities. Notably, the COVID-19 crisis has turned out to be a catalyst for European pharma companies to revisit their supply chain risk management strategies and expedite the adoption of advanced analytics models to build powerful supply chains immune to disruptions.
Book a FREE solution demo to gain a limited-period free license to access our supply chain analytics platforms.
According to Quantzig’s supply chain analytics experts, “As COVID-19 continues to spread across geographies, the pharma industry in Europe remains committed to the global efforts to curb the outbreak and develop new formulations to tackle future outbreaks.”
Challenges Faced by European Pharma Companies Amidst the Crisis
#1 How to ensure continuous global supply of critical COVID-19 test kits, masks, and ventilators to treat patients in the face of the ongoing supply chain disruptions and medical device shortages?
#2 As COVID-19 spreads rapidly, what measures must be taken to avoid disruptions to R&D, including ongoing and planned clinical trials?
#3 What can the pharma industry do to help patients and customers make it through challenging times like these?
Talk to our analytics experts for comprehensive insights and personalized recommendations on how we help pharma companies address such issues.
Leading pharma companies in Europe still follow a reactive approach in responding to supply chain disruptions. Hence one gets to witness a varying degree of professionalization of supply chain risk management across Europe. Considering the current global scenario, supply chain risk management can have a huge financial impact on the organization. Our experts believe, collaborating with suppliers, maintaining close relations with third-party vendors, and performing systematic audits is just a part of the general business practice and businesses must go a step ahead and devise short-term action plans to respond to the immediate challenges posed by the crisis.
We now offer a comprehensive COVID-19 business support package that covers various aspects of supply chain management including, financial reporting, and crisis management, and working capital management.
About Quantzig
Quantzig is a global analytics and advisory firm with offices in the US, UK, Canada, China, and India. For more than 15 years, we have assisted our clients across the globe with end-to-end data modeling capabilities to leverage analytics for prudent decision making. Today, our firm consists of 120+ clients, including 45 Fortune 500 companies. For more information on our engagement policies and pricing plans, visit: https://www.quantzig.com/request-for-proposal
